Count | |
| 13 | |
| 7 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 3 | |
| 2 | |
Antiparkinson Agents/pharmacokinetics/pharmacology/*therapeutic use | 1 |
Antiparkinson Agents/adverse effects/pharmacokinetics/*therapeutic use | 1 |
Antiparkinson Agents/adverse effects/*pharmacology/therapeutic use | 1 |
Antiparkinson Agents/*adverse effects/blood/*therapeutic use | 1 |
Antiparkinson Agents/adverse effects/*pharmacokinetics/*therapeutic use | 1 |
Antiparkinson Agents/adverse effects/*pharmacokinetics/therapeutic use | 1 |
| 7 | |
| 3 | |
| 1 | |
| 1 | |
| 2 | |
| 2 | |
| 1 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
Antiparkinson Agents/adverse effects/pharmacokinetics/*pharmacology | 1 |
Antiparkinson Agents/*administration & dosage/adverse effects | 2 |
Antiparkinson Agents/administration & dosage/blood/*pharmacokinetics | 2 |
| 9 | |
| 2 | |
| 52 | |
| 3 | |
| 6 | |
| 2 | |
| 1 | |
| 57 | |
| 2 | |
| 1 | |
| 29 | |
| 221 | |
| 203 | |
| 3 | |
| 2 | |
| 2 | |
| 2 | |
| 29 | |
| 11 | |
| 15 | |
| 3 | |
| 1 | |
| 1 | |
| 104 | |
| 228 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 3 | |
| 1 | |
| 131 | |
| 10 | |
| 19 | |
| 19 | |
| 6 | |
| 43 | |
| 9 | |
| 10 | |
| 24 | |
| 33 | |
| 1 | |
| 1 | |
| 29 | |
| 1 | |
| 18 | |
| 5 | |
| 24 | |
| 57 | |
| 15 | |
| 9 | |
| 13 | |
| 1 | |
| 29 | |
| 7 | |